Skip to main content

Advertisement

SpringerLink
Log in

High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The RAPP-01 clinical trial compared two adjuvant chemotherapies, doxorubicin plus docetaxel (arm A) versus doxorubicin plus cyclophosphamide (arm B), in 627 women with breast cancer. It stopped prematurely when three severe adverse events occurred among patients with febrile neutropenia (FN), all in the arm A. FN occurred in 40.8 % (126/311) in arm A versus 7.1 % (22/316) in arm B. We investigated Single Nucleotide Polymorphisms (SNPs) in drug transporter and metabolism genes potentially incriminated in this excess of FN. Using a dedicated DNA chip, we tested association of SNPs belonging to 97 transporter and 68 metabolizing genes with FN occurrence in 155 patients enrolled in the RAPP-01 trial, 85 in arm A and 70 in arm B. Association study in the 85 patients receiving docetaxel identified two SNPs, rs4762699 and rs2857468, both located in the SLCO1A2 gene. Haplotype T–T was associated with a high risk of FN: 83.3 % of patients with at least one copy of T–T versus 32.8 % in patients with other haplotypes (odds ratio = 10.25, P = 1.4e−4). In a multivariate logistic model adjusted for treatment arm, effect of haplotype T–T remained significant (odds ratio = 6.84, P = 1.15e−4). FN in patients receiving docetaxel in the RAPP-01 trial is significantly associated with the haplotype T–T in rs4762699 and rs2857468 in the SLCO1A2 transporter gene. This result should be validated in an independent cohort.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Brain EG, Bachelot T, Serin D, Kirscher S, Graic Y, Eymard JC, Extra JM, Combe M, Fourme E, Nogues C et al (2005) Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA 293(19):2367–2371

    Article  CAS  PubMed  Google Scholar 

  2. Woodward EJ, Twelves C (2010) Scheduling of taxanes: a review. Curr Clin Pharmacol 5(3):226–231

    Article  CAS  PubMed  Google Scholar 

  3. Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6(4):229–239

    Article  CAS  PubMed  Google Scholar 

  4. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y (2008) Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 99(5):967–972

    Article  CAS  PubMed  Google Scholar 

  5. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266

    Article  PubMed  Google Scholar 

  6. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R (1996) Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56(6):1296–1302

    CAS  PubMed  Google Scholar 

  7. Sparreboom A, Van Tellingen O, Scherrenburg EJ, Boesen JJ, Huizing MT, Nooijen WJ, Versluis C, Beijnen JH (1996) Isolation, purification and biological activity of major docetaxel metabolites from human feces. Drug Metab Dispos 24(6):655–658

    CAS  PubMed  Google Scholar 

  8. Rizzo R, Spaggiari F, Indelli M, Lelli G, Baricordi OR, Rimessi P, Ferlini A (2010) Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 124(2):593–598

    Article  CAS  PubMed  Google Scholar 

  9. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A (2000) Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 6(7):2598–2603

    PubMed  Google Scholar 

  10. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102(5):1016–1023

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM, Wojnowski L (2004) The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 279(37):38379–38385

    Article  CAS  PubMed  Google Scholar 

  12. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 274(10):6043–6046

    Article  CAS  PubMed  Google Scholar 

  13. Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276(18):14581–14587

    Article  CAS  PubMed  Google Scholar 

  14. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A (2005) Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4(8):815–818

    Article  CAS  PubMed  Google Scholar 

  15. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH (2005) MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116(5):824–829

    Article  CAS  PubMed  Google Scholar 

  16. Chew SC, Singh O, Chen X, Ramasamy RD, Kulkarni T, Lee EJ, Tan EH, Lim WT, Chowbay B (2011) The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 67(6):1471–1478

    Article  CAS  PubMed  Google Scholar 

  17. Chew SC, Lim J, Singh O, Chen X, Tan EH, Lee EJ, Chowbay B (2013) Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRalpha and HNF4alpha) on docetaxel disposition in Chinese nasopharyngeal cancer patients, Eur J Clin Pharmacol

  18. Hor SY, Lee SC, Wong CI, Lim YW, Lim RC, Wang LZ, Fan L, Guo JY, Lee HS, Goh BC et al (2008) PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J 8(2):139–146

    Article  CAS  PubMed  Google Scholar 

  19. Tham LS, Holford NH, Hor SY, Tan T, Wang L, Lim RC, Lee HS, Lee SC, Goh BC (2007) Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin Cancer Res 13(23):7126–7132

    Article  CAS  PubMed  Google Scholar 

  20. Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ (2013) The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genom 23(1):29–33

    Article  CAS  Google Scholar 

  21. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Treluyer JM (2006) Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79(6):570–580

    Article  CAS  PubMed  Google Scholar 

  22. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J et al (2011) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32

    Article  CAS  PubMed  Google Scholar 

  23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70(2):425–434

    Article  PubMed Central  PubMed  Google Scholar 

  24. Benjamini YHY (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 57(1):12

    Google Scholar 

  25. Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78(3):260–277

    Article  CAS  PubMed  Google Scholar 

  26. Zhou F, Zheng J, Zhu L, Jodal A, Cui PH, Wong M, Gurney H, Church WB, Murray M (2013) Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2. AAPS J 15(4):1099–1108

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Gong IY, Kim RB (2013) Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 28(1):4–18

    Article  CAS  PubMed  Google Scholar 

  28. von Minckwitz G (2007) Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother 8(4):485–495

    Article  Google Scholar 

  29. Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ et al (2013) Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol 31(34):4283–4289

    Article  CAS  PubMed  Google Scholar 

  30. von Minckwitz G, Kummel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C et al (2008) Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 19(2):292–298

    Article  Google Scholar 

  31. Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS, Shahin S, Dreiling L, Saven A (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of Four multicenter, double-blind, randomized phase II studies. J Oncol Pract 6(3):133–140

    Article  PubMed Central  PubMed  Google Scholar 

  32. Jenkins P, Scaife J, Freeman S (2012) Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Ann Oncol 23(7):1766–1771

    Article  CAS  PubMed  Google Scholar 

  33. Church D, Kerr R, Domingo E, Rosmarin D, Palles C, Maskell K, Tomlinson I, Kerr D (2014) ‘Toxgnostics’: an unmet need in cancer medicine. Nat Rev Cancer 14(6):440–445

    Article  CAS  PubMed  Google Scholar 

  34. Jabir RS, Naidu R, Annuar MA, Ho GF, Munisamy M, Stanslas J (2012) Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics 13(16):1979–1988

    Article  CAS  PubMed  Google Scholar 

  35. Brain EG, Debled M, Eymard JC, Bachelot T, Extra JM, Serin D, Combe M, Fourme E: Final results of the RAPP-01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high-risk node negative and limited node positive (≤3) breast cancer patients. Abstract #4101, 31st Annual San Antonio Breast Cancer Cancer Symposium. Breast Cancer Res Treat December 10–14, 2008, 107 (suppl 1)

Download references

Acknowledgments

We thank Hôpital René Huguenin, the sponsor of the RAPP-01 trial and the center of biological resources of Institut Curie for DNA extraction. We thank the French network ≪Réseau de Pharmacogénétique des Anti Cancéreux≫ (REPAC), INSERM, and the pharmacogenetic program supervised by Professeur Pierre Laurent-Puig (University Paris Descartes) for the use of the dedicated DNA chip REPAC.

Authors contributions

E Brain, M. Debled, C. Callens, I. Bièche: conception and design. C. Callens, M. Delord, I. Turbiez-Stalain: acquisition of datas. C. Callens, M. Delord, I. Bièche, E. Brain: analysis and interpretation of data. C. Callens, M. Delord, I. Bièche, M. Debled, C. Veyret, E. Brain: writing, review and /or revision of the manuscript. C. Callens, M. Delord, I. Turbiez-Stalain: administrative, technical or material support. E. Brain, M. Debled, I. Bièche: study supervision.

Funding

Sanofi-Aventis and La Ligue Contre le Cancer du Département des Yvelines (78).

Author information

Authors and Affiliations

  1. Institut Curie, Service de Génétique, Unité de Pharmacogénomique, 26 rue d’Ulm, 75005, Paris, France

    Céline Callens & Ivan Bièche

  2. Département d’Oncologie médicale, Centre Henri Becquerel, rue d’Amiens, 76000, Rouen, France

    Marc Debled & Corinne Veyret

  3. Plateforme de Bioinformatique et Biostatistique, Institut Universitaire d’Hématologie, Université paris Diderot, Sorbonne Paris Cité, 1 avenue Claude Vellefaux, 75010, Paris, France

    Marc Delord

  4. Département de Recherche Clinique, Institut Curie-Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France

    Isabelle Turbiez-Stalain & Etienne Brain

  5. Département d’Oncologie médicale, Institut Curie-Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France

    Etienne Brain

Authors
  1. Céline Callens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Debled
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marc Delord
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isabelle Turbiez-Stalain
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Corinne Veyret
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ivan Bièche
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Etienne Brain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Etienne Brain.

Ethics declarations

Conflict of interest

No potential conflicts of interest were reported by authors.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Callens, C., Debled, M., Delord, M. et al. High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial. Breast Cancer Res Treat 153, 383–389 (2015). https://doi.org/10.1007/s10549-015-3552-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-015-3552-7

Keywords

Search

Navigation